Kallikrein 15 (KLK15) Human shRNA Lentiviral Particle (Locus ID 55554)

CAT#: TL303640V

KLK15 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

Product Images

GFP signal was observed under microscope at 48 hours after transduction of TL303640A virus into HEK293 cells. TL303640A virus was prepared using lenti-shRNA TL303640A and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of TL303640B virus into HEK293 cells. TL303640B virus was prepared using lenti-shRNA TL303640B and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL303640D] virus into HEK293 cells. [TL303640D] virus was prepared using lenti-shRNA [TL303640D] and TR30037 packaging kit.

Specifications

Product Data

• Locus ID: 55554
• Synonyms: ACO; HSRNASPH
• Vector: pGFP-C-shLenti
• Format: Lentiviral particles
• RefSeq: NM_001277081, NM_001277082, NM_017509, NM_023006, NM_138563, NM_138564, NR_102274, NM_017509.1, NM_017509.2, NM_017509.3, NM_138564.1, NM_138563.1, NM_001277082.1, NM_001277081.1, NM_023006.1, BC069507, BC069507.1, BC069480, BC069518, BC126137, BC144045, BC144046, BC144047
• UniProt ID: Q9H2R5
• Summary: Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. In prostate cancer, this gene has increased expression, which indicates its possible use as a diagnostic or prognostic marker for prostate cancer. The gene contains multiple polyadenylation sites and alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2008]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).